Thursday, October 10, 2013

The Economic Success of the Multinational Corporations in Puerto Rico contrasts with Puerto Rico's Failed Economy !!

Apple's not alone in stashing cash in offshore tax havens as 18 of the U.S.' biggest companies skirt $92 billion in taxes: Report
  • Some of the U.S.' largest corporations keep much of their profits in places like Ireland, the Bahamas and the Caymen Islands, where corporate tax rates can be as low as zero
  • General Electric holds roughly $110 billion in places like the Bahamas, Bermuda, Ireland and Singapore
  • U.S. corporate tax rates range from 30-percent to 39-percent

Read more: http://www.dailymail.co.uk/news/article-2335451/Apples-stashing-cash-offshore-tax-havens-18-U-S-biggest-companies-skirt-92-billion-taxes-Report.html#ixzz2hNefGTME 
_________________________________________________________________

Puerto Rico Pharmaceuticals & Healthcare Report Q4 2013 - New Market Research Report

Boston, MA -- (SBWIRE) -- 10/10/2013 -- Puerto Rico's importance as a major production hub for multinational pharmaceutical companies will continue to diminish on account of patent expirations, production quality issues, increasing labour and operational costs, and a potential tax increase by the local government. However, the pharmaceutical industry will still be an economic mainstay for the country, as evidenced by the recent investment by US major Bristol-Myers Squibb (BMS). The island's incentives will continue to attract multinational drugmakers' investment provided the market's appeal continues to offset the effect of negative issues.

View Full Report Details and Table of Contents

Headline Expenditure Projections- 
Pharmaceuticals: US$2.92bn in 2012 to US$3.06bn in 2013; +4.6% in local currency terms. Forecast broadly in line with the previous quarter's projection.
- Healthcare: US$7.53bn in 2012 to US$7.81bn in 2013; +3.7% in local currency terms. Forecast unchanged from the previous quarter.
Risk/Reward Rating: In our latest Pharmaceutical Risk/Reward Rating (RRR) regional assessment, Puerto Rico remains ranked third of the 17 markets surveyed in the Americas region, trailing only the US and Canada. While its high per capita spending on medicines distinguishes it from countries in Latin America, its longer-term potential is under pressure due to an economic slowdown and falling population numbers.